AI Article Synopsis
Article Abstract
Objectives: Aberrant intra-epithelial lymphocytes (IELs) are the hallmark of refractory coeliac disease type II RCDII and considered a premalignant cell population from which aggressive enteropathy-associated T cell lymphoma (EATL) can evolve. The aim of this study was to gain further insight in the origin and characteristics of aberrant IELs by analysing T-cell receptor (TCR) rearrangements, and by immunophenotypic analysis of aberrant IELs.
Design: Duodenal biopsies from 18 RCDII patients and three RCDII cell lines were analysed for the presence of TCR delta, gamma, and beta rearrangements. In addition, IELs isolated from biopsies derived from RCDII patients were phenotypically analysed.
Results: Aberrant IELs showed an upregulated expression of granzyme B and decreased expression of PCNA. TCR rearrangements in the aberrant IEL population in biopsies of RCDII patients were heterogenic, which is most likely due to a variation in maturity. Similarly, RCDII cell lines displayed a heterogenic TCR rearrangement pattern.
Conclusion: Aberrant IELs originate from deranged immature T lymphocytes and display clear differentiation to a cytotoxic phenotype. Aberrant IELs displayed different stages of maturity between RCDII patients, of which only the patients harbouring the most mature aberrant IEL population developed an EATL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.molimm.2012.01.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Refractory Celiac Disease: What the Gastroenterologist Should Know.
Int J Mol Sci
September 2024
Gastroenterology Department, Hospital de Vila Franca de Xira, 2600-009 Lisbon, Portugal.
Article Synopsis
- Fewer than 1% of celiac disease patients develop refractory celiac disease (RCD), but all gastroenterologists should understand its serious implications, such as high mortality and risk of enteropathy-associated T cell lymphoma (EATL).
- Diagnosing RCD involves complex tests to differentiate it from other gastrointestinal issues and requires specialists, especially to distinguish between type I and type II RCD.
- Treatment options like immunosuppression work for milder cases, but effectiveness is limited in type II RCD, often leading to temporary improvements without halting disease progression.
Enduring Clinical Remission in Refractory Celiac Disease Type II With Tofacitinib: An Open-Label Clinical Study.
Clin Gastroenterol Hepatol
November 2024
Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands. Electronic address:
Refractory celiac disease type 2 (RCDII) is a rare condition with high mortality because of a lack of effective treatment strategies. RCDII is caused by clonal expansion of intraepithelial lymphocytes (IELs). Gain-of-function JAK1 mutations are frequently found in these cells.
View Article and Find Full Text PDFUpdate on the Pathogenesis of Enteropathy-Associated T-Cell Lymphoma.
Diagnostics (Basel)
August 2023
Department of Histopathology, Trinity College Dublin, D02 PN40 Dublin, Ireland.
EATL is an aggressive T-cell non-Hodgkin lymphoma with poor prognosis and is largely localized to the small intestine. EATL is closely associated with coeliac disease (CD) and is seen mostly in patients originating from Northern Europe. Various factors are associated with an increased risk of developing EATL, such as viral infection, advanced age, being male, and the presence of the HLA-DQ2 haplotype.
View Article and Find Full Text PDFSingle-Cell Analysis of Refractory Celiac Disease Demonstrates Inter- and Intra-Patient Aberrant Cell Heterogeneity.
Cell Mol Gastroenterol Hepatol
June 2022
Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:
Background & Aims: Refractory celiac disease type II (RCDII) is a rare indolent lymphoma in the small intestine characterized by a clonally expanded intraepithelial intracellular CD3surfaceCD3CD7CD56 aberrant cell population. However, RCDII pathogenesis is ill-defined. Here, we aimed at single-cell characterization of the innate and adaptive immune system in RCDII.
View Article and Find Full Text PDFThe Intracellular Intensity of CD3 on Aberrant Intraepithelial Lymphocytes Is a Prognostic Factor of the Progression to Overt Lymphoma in Refractory Celiac Disease Type II (Pre-Enteropathy-Associated T Cell Lymphoma).
Dig Dis
November 2020
Department of Immunology, Hospital Universitario Ramón y Cajal, Madrid, Spain,
Background: Refractory celiac disease type II (RCD-II) is a very rare yet severe complication of celiac disease (CD) with a 50% rate of progression to Enteropathy-associated T-cell lymphoma (EATL). Timely diagnosis and treatment of RCD-II is of the essence and requires the identification of a population of frequently clonal, phenotypically aberrant intraepithelial lymphocytes (IELs). Flow Cytometry of intestinal IELs is the recommended method to identify the aberrant surface CD3-negative (sCD3-) intracytoplasmic CD3-positive (icCD3ε+) IELs, and a proportion of >20% is diagnostic of RCD-II.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!